Background.We have observed a number of patients who fail to develop coccidioidal complement fixing (CF) antibody (immunoglobulin [IgG]) after the initiation of early antifungal therapy. Although this is the first description of this phenomenon in mycology, a precedent for the abrogation of the immune response has been observed in other conditions, including primary syphilis and primary Lyme disease.Methods.We conducted a retrospective case-control study to determine any patient-specific risk factors associated with this observation. Additionally, in vitro analysis of the coccidioidal CF (IgG) antigen (Cts1) was performed after Coccidioides was grown under escalating fluconazole concentrations.Results.Seventeen patients persistently positive for coccidioidal IgM antibodies without developing an IgG response (cases) were compared with 64 consecutive patients who did develop coccidioidal CF (IgG) antibodies (controls). Early treatment with antifungals (within 2 weeks of symptom onset) was associated with an abrogation of IgG antibody production (P
CITATION STYLE
Thompson, G. R., Lunetta, J. M., Johnson, S. M., Taylor, S., Bays, D., Cohen, S. H., & Pappagianis, D. (2011). Early treatment with fluconazole may abrogate the development of IgG antibodies in coccidioidomycosis. Clinical Infectious Diseases, 53(6). https://doi.org/10.1093/cid/cir466
Mendeley helps you to discover research relevant for your work.